Trivitron Healthcare today announced its strategic partnership with Diasorin Group. The partners will cater to the Indian InVitro Diagnostics market of around $500 million and Indian Immunodiagnostic market of around $165 million.
The partnership has formed the capital companies DiaSorin Trivitron Healthcare Pvt Ltd, in which the parties will have 51 per cent and 49 per cent stakes respectively. The company will directly operate in the India diagnostics market and the company expects it will play a key role in the immunodiagnostic market over the next three years.
G S K Velu, founder and MD of Trivitron Group of Companies said that combining the strengths of Diasorin and Trivitron, in the next three years we attempt to reach leadership position in the Indian Immunoassay segment.
Trivitron has been a contributor in IVD segment, wherein the company installed Immunoassay analyzersin almost 70 per cent of labs in India. It is the first company to launch the Chemi Luminescence Immuno Assay platform in India.